OCT ANGIOGRAPHY FOR GLAUCOMA

Considering the vasculature in disease management.

BY GREG CALDWELL, OD, FAAO

One of the greatest benefits of OCT angiography (OCTA) is that it allows users to observe, measure, and monitor capillaries located in the retina and surrounding the optic nerve. Images can be obtained without the injection of dyes into the body, thereby eliminating risk of morbidity or mortality. OCTA also requires less time than a dye-based procedure. These instruments perform approximately 70,000 A-scans per second, which allows them to visualize individual layers of the retinal vasculature. The first device to use this technology received FDA clearance in September 2015, and devices are now commercially available from Optovue, Carl Zeiss Meditec, and Heidelberg Engineering. I am most familiar with the Angiovue imaging system (Optovue).

This article examines how OCTA can assist clinicians in the diagnosis and management of glaucoma.

THE ROLE OF THE VASCULATURE IN GLAUCOMA

Retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) loss in glaucoma is well recognized. The RNFL is measured in a circle around the optic nerve, and the GCC is measured in the macular region. The
relationship between structure (RNFL and GCC) and function (visual field) in glaucoma is a subject of extensive study, but the role of the vasculature (optic nerve and retinal vessel density) is poorly understood.

Researchers are currently trying to determine whether the vessel density of the radial peripapillary capillaries (RPCs) and retina is compromised before the RNFL and GCC in glaucoma. OCTA can measure the RPCs around the optic nerve and the superficial and deep retinal capillaries in the macula. The technology shows early changes in retinal and optic disc vessel density.¹

THE TECHNOLOGY IN PRACTICE

In the clinic, having the ability to compare structural and vascular status with OCTA gives me confidence when I am deciding whether to observe a patient or to commence glaucoma treatment. It also enhances my ability to detect glaucomatous progression.

Findings in Healthy Eyes

Figure 1 shows a normal OCTA report of the optic nerve RPCs in a healthy 60-year-old man without glaucoma. The RNFL thickness is 110 µm and 107 µm superiorly and inferiorly on the hemifield analysis and 126 µm and 132 µm superiorly and inferiorly on the quadrant analysis. The vessel density metrics display the percentage of area occupied by OCTA-detected vasculature based on the RPC slab. Figure 1 shows normal RPC vessel density measurements of 52% and 53% superiorly and inferiorly on the hemifield analysis and 52% and 53% in the quadrant analysis.

Figure 2 demonstrates normal layers of retinal vasculature and structure. The superficial vessel density numbers are 51% superior perifovea/55% superior parafovea and 51% inferior perifovea/55% inferior parafovea on the hemifield analysis. On the inner...
retinal thickness scan, the numbers are 105 µm superior perifovea/124 µm superior parafovea and 101 µm inferior perifovea/122 µm inferior parafovea. Vessel density and inner retinal thickness are symmetric and intact; it is worth keeping in mind that the GCC resides in the inner retina.

Most OCTA instruments can create a montage of optic nerve and retina scans. Figure 3 displays montages for the right and left eyes of this patient. The RPCs and retinal capillaries are intact.

**Findings in Glaucomatous Eyes**

A 68-year-old woman with primary open-angle glaucoma requested a second opinion on her management. At the time of presentation, the patient had been treated for glaucoma for more than 10 years. Her therapeutic regimen included dorzolamide 2% twice daily in each eye (OU) and bimatoprost ophthalmic solution 0.01% (Lumigan, Allergan) once daily OU. She had undergone cataract surgery and IOL implantation combined with placement of an iStent Trabecular Micro-Bypass Stent (Glaukos) in her left eye (OS) in 2017.

Upon examination, IOP was 22 mm Hg in the patient’s right eye (OD) and 16 mm Hg OS using Goldmann applanation tonometry. Pachymetry measured 569 µm OD and 575 µm OS. OCT imaging showed thinning of the RNFL in the inferior and temporal quadrants OD and in the inferior and superior quadrants OS, worse inferiorly. The GCC was compromised inferiorly in each eye (Figure 4). Visual field testing demonstrated functional loss OU that was worse OS, and both eyes had demonstrable visual field loss in the macular region (Figure 5).

OCTA of the optic nerve OD showed RNFL thickness of 95 µm superiorly and 73 µm inferiorly on the hemifield analysis and 118 µm superiorly and 77 µm inferiorly on the quadrant analysis. RNFL thickness OS was 66 µm superiorly and 58 µm inferiorly in the hemifield analysis and 69 µm superiorly and 61 µm inferiorly in the quadrant analysis. RPC vessel density OD was 49% superiorly and 48% inferiorly on the hemifield analysis and 50% and 46%, respectively, in the quadrant analysis (Figure 6A). RPC vessel density OS was 41% superiorly and 38% inferiorly on the hemifield analysis and 39% and 36%, respectively, in the quadrant analysis (Figure 6B). The RNFL and RPCs were compromised OU, but more so OS. There was a small inferior wedge defect OD and a larger inferior wedge defect OS, visible on both the RNFL thickness map and RPC vessel density map.

OCTA of the retina measured vessel density of 45% superior perifovea/52% superior parafovea and 37% inferior perifovea/52% inferior parafovea OD on the hemifield analysis. On the inner...

---

**Figure 4.** OCT imaging shows thinning of the RNFL in the inferior and temporal quadrants OD and in the inferior and superior quadrants OS, worse inferiorly. The GCC is compromised inferiorly in each eye, worse OS.

**Figure 5.** Visual field testing demonstrates functional loss OU, worse OS (A). Both eyes have demonstrable visual field loss in the macular region.
retinal thickness map, the numbers were 92 µm superior perifovea/100 µm superior parafovea in the superior quadrant and 82 µm inferior perifovea/86 µm inferior parafovea (Figure 7A).

Superficial vessel density OS was 45% superior perifovea/48% superior parafovea and 33% inferior perifovea/38% inferior parafovea on hemifield analysis. On the inner retinal thickness map, the numbers were 78 µm superior perifovea/94 µm superior parafovea and 54 µm inferior perifovea/51 µm inferior parafovea (Figure 7B). The retinal vessel density and inner retinal thickness were compromised OU but to a greater extent OS.

The wedge defect was seen to continue and widen on both the retinal thickness and vessel density maps. The defect could also be appreciated in the macula on the visual field tests. Montages for the eyes showed compromised capillaries, worse OS (Figure 8).

My clinical impression was that the patient’s glaucoma was not well controlled OD. Because she needed cataract surgery, she underwent that procedure combined with glaucoma surgery using a Kahook Dual Blade (New World Medical). Postoperative IOP on medication was 11 mm Hg OD and 15 mm Hg OS.

Time will tell if these treated IOPs are low enough to stop or slow the progression of glaucoma. OCTA of the optic

Figure 6. RPC vessel density in the right eye is 49% superiorly and 48% inferiorly on the hemifield analysis and 50% and 46%, respectively, in the quadrant analysis (A). RPC vessel density OS is 41% superiorly and 38% inferiorly on the hemifield analysis and 39% and 36%, respectively, in the quadrant analysis (B).

Figure 7. In the right eye, the numbers are 92 µm superior perifovea/100 µm superior parafovea and 82 µm inferior perifovea/86 µm inferior parafovea on the inner retinal thickness map (A). In the left eye, the numbers are 78 µm superior perifovea/94 µm superior parafovea and 54 µm inferior perifovea/51 µm inferior parafovea on the inner retinal thickness map (B).
nerve and retina with vessel density measurements is another option for monitoring the patient’s status.

**A USEFUL TOOL**

The ability of OCTA to measure loss of vessel density can help clinicians detect glaucoma earlier by providing an additional marker of disease damage. I find this information particularly helpful with patients who perform poorly on visual field tests and those who have RNFL artifacts on OCT analysis.

Measurements of vessel density can also help one to gauge a patient’s risk of disease progression. I order OCTA scans of all my patients with glaucoma and glaucoma suspects. Much remains to be learned about this technology and its applications, but I am hopeful that it will increase clinicians' understanding of this complex disease, and this will ultimately benefit patients.


---

**GREG CALDWELL, OD, FAAO**

- Owner, Optometric Education Consultants in Scottsdale, Arizona; St. Paul, Minnesota; Quebec City, Canada; and Nashville, Tennessee
- grubod@gmail.com
- Financial disclosure: Administrator (OCT Connect on Facebook); Advisory board (Allergan, BioTissue, Sight Sciences, Sun Pharma); Lecture fees and honoraria (Aerie Pharmaceuticals, Alcon, Allergan, BioTissue, Optovue, Sun Pharma); Pennsylvania medical director and member, Credential Committee (Envolve)